Pfizer Will Agree to Pay $894 Million to Settle Celebrex and Bextra Claims

Pfizer has recently announced that it will “resolve substantially all of the personal injury cases, consumer fraud cases and state attorneys general claims involving its non-steroidal anti-inflammatory (NSAID)” pain medications Bextra and Celebrex, which Pfizer voluntarily withdrew from the U.S. market in 2005.

Pfizer, the world’s biggest drugmaker, was being sued over allegations that the drugs increased the risk of heart attacks or strokes after a similar pill, Merck & Co.’s Vioxx, was pulled from the market over the same side effects in 2004.

Despite this, Celebrex is still sold, generating $2.3 billion for Pfizer last year, while Bextra was recalled over a rare skin condition in 2005. Additionally, Pfizer still claims there “is no evidence that Celebrex, when taken at lower doses, poses a risk to the heart.”

According to a study though recently presented at the American College of Cardiology, “patients taking the biggest Celebrex dose of 400 milligrams twice a day tripled their chance of a heart attack or stroke, compared with people taking a placebo.”

PBM has represented clients in Vioxx and Celebrex claims. If you are someone you know has been injured as a result of a medication, please contact our law firm for a free consultation.